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1961and metabolic syndrome has evolved over the past few
decades, mostly due to changes in diet and lifestyle.
Approximately 1 of 3 U.S. adults currently has metabolic
syndrome (1). As a result, we have witnessed an increasing
prevalence of elevated triglyceride-rich remnant lipoproteins,
characteristic of insulin resistance. These lipoproteins
include very-low-density lipoproteins (VLDL) and their
remnants, intermediate-density lipoproteins, and chylomi-
cron remnant particles, whose contribution to atherogenic
risk is accounted for by non–HDL-C not LDL-C.
Current guidelines recommend using non–HDL-C as a
secondary treatment target in patients with triglyceride
levels200 mg/dl (3–5), setting non–HDL-C goals 30 mg/dl
higher than respective LDL-C goals. However, some reports
have suggested using non–HDL-C goals at the same pop-
ulation percentiles as the respective LDL-C goals (6,7).
In this report, we examine patient-level discordance
between non–HDL-C and LDL-C percentiles at different
LDL-C and triglyceride strata and implications for risk
assessment and treatment.Table 1
Equivalent Population Percentiles of LDL-C and Non–
HDL-C From the Very Large Database of Lipids Study
Population Percentile LDL-C (mg/dl) Non–HDL-C (mg/dl)
1st 37 60
5th 54 76
10th 63 86
15th 70* 93*
20th 77 100
25th 82 106
44th 100* 125*
50th 106 132
72nd 130* 157*
75th 134 161
90th 160* 190*
95th 177 209
97th 190* 223*
99th 215 251
*LDL-C cutpoints in worldwide guidelines.
HDL-C ¼ high-density lipoprotein cholesterol; LDL-C ¼ low-density lipoprotein cholesterol.Methods
Study population. We examined consecutive lipid proﬁles
from 1,310,440 U.S. adults 18 years of age with triglyc-
eride levels <400 mg/dl who underwent direct ultracen-
trifugation of cholesterol by the vertical auto proﬁle (VAP;
Atherotech Diagnostics Lab, Birmingham, Alabama) from
2009 to 2011 (8,9). “Consecutive” indicates that we only
included the ﬁrst available lipid proﬁle for each patient.
Consistent with routine clinical practice, LDL-C levels
were estimated using the Friedewald formula, thus
excluding patients with triglyceride levels 400 mg/dl
(9,10).
VAP lipid measurement. The VAP is an inverted rate
zonal, single vertical spin, density-gradient ultracentrifuga-
tion technique that directly measures cholesterol concen-
trations of the 5 lipoprotein classes (LDL-C, VLDL
cholesterol, intermediate-density lipoprotein cholesterol,
HDL-C, and lipoprotein[a]) and their subclasses. Triglyc-
eride levels were directly measured using the Abbott
Architect C8000 system (Abbott Park, Illinois) (8,9). The
accuracy of VAP lipid parameters was cross-validated with
reference standards as previously described (9).
Data management. Raw individual patient data were
extracted at Atherotech, cleaned of duplicate samples, and
then de-identiﬁed and transferred to the senior investigator.
The master database, the Very Large Database of Lipids
(VLDL), is maintained at The Johns Hopkins Hospital
(Baltimore, Maryland) and registered at clinicaltrials.gov
(NCT01698489). The Johns Hopkins Institutional Review
Board declared the study exempt.
Statistical analysis. Friedewald-estimated LDL-C levels
were calculated as [total cholesterol –HDL-C – triglycerides/5].
Non–HDL-C levels were calculated as [total cholesterol –
HDL-C]. We assigned population percentiles to LDL-C andnon–HDL-C levels and then
determined the percentiles corre-
sponding to LDL-C cutpoints in
current guidelines (70, 100, 130,
160, and 190 mg/dl) (3–5).
Reclassiﬁcation was deﬁned as
present when the non–HDL-C
level reclassiﬁed a patient within
or to a higher (upward) or lower
(downward) treatment category
compared with the Friedewald
LDL-C level. The analysis was
performed using guideline-based non–HDL-C cutpoints,
deﬁned as 30 mg/dl higher than LDL-C cutpoints, and
percentile-based cutpoints, deﬁned as those at equivalent
percentiles to LDL-C cutpoints. We focused on upward
reclassiﬁcation because current guidelines recommend using
non–HDL-C level only as a secondary treatment target after
the LDL-C target is reached; thus, downward reclassiﬁca-
tion becomes irrelevant.
Statistical analyses and logarithmically scaled pseudocolor
density plots were generated in R Version 2.15.1 (Vienna,
Austria) and Stata Version 11.0 (College Station, Texas).Results
Population characteristics. Patients were 59  15 years
of age (mean  SD), 52% were women, and lipid parameter
distributions were nearly superimposable with recent lipid
data from the 2007 to 2008 National Health and Nutrition
Examination Survey (11), as previously described by our
group (9) (Online Fig. 1).
Population percentiles. LDL-C cutpoints of 70, 100, 130,
160, and 190 mg/dl were at the same population percentiles
as non–HDL-C values of 93, 125, 157, 190, and 223 mg/dl,
respectively (Table 1).
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1962Non–HDL-C and LDL-C percentile discordance. We
visually assesseddiscordance betweenLDL-Candnon–HDL-
C percentiles and found greater discordance at lower LDL-C
and higher triglyceride levels (Fig. 1). Similarly, the absolute
difference between non–HDL-C and LDL-C percentiles was
more pronounced with greater in-group variation at lower
LDL-C and higher triglyceride levels (Online Fig. 2).
Reclassiﬁcation of treatment category by non–HDL-C
level. When using conventional non–HDL-C cutpoints,
non–HDL-C levels reclassiﬁed 10.5% (n ¼ 137,744) of the
studygroupupward and22.3%(n¼ 291,499) downward.Using
percentile-based cutpoints, 14.2% (n ¼ 186,106) were reclas-
siﬁed upward and 13.7% (n ¼ 178,860) downward (Fig. 2).
Upward reclassiﬁcation occurred more frequently at lower
LDL-C and higher triglyceride levels (for additional
discussion, see Reclassiﬁcation Analysis in the Online
Appendix). Of patients with an LDL-C level <70 mg/dl,
15% had a non–HDL-C level 100 mg/dl (the guideline-
based cutpoint) and 25% had a non–HDL-C level
93 mg/dl (the percentile-based cutpoint); these valuesFigure 1 Patient-Level Discordance Between Population Percentiles
(A) The total population and (B) 4 different triglyceride categories. The density of data is
patients per pixel, from light blue to purple.were 22% and 50%, respectively, if triglyceride levels were
concurrently 150 to 199 mg/dl (Fig. 3A). Similarly, of
patients with LDL-C levels between 70 and 99 mg/dl,
12% had a non–HDL-C level 130 mg/dl and 17% had a
non–HDL-C level 125 mg/dl; these values were
17% and 35%, respectively, if triglyceride levels were
concurrently 150 to 199 mg/dl (Fig. 3B).Discussion
Our study highlights the magnitude of patient-level
discordance between LDL-C and non–HDL-C percen-
tiles. They are most discordant when accuracy is most
crucial, at low LDL-C and high triglyceride levels. There-
fore, conventional non–HDL-C cutpoints for high-risk
patients may need to be lowered to match percentiles of
LDL-C cutpoints.
Non–HDL-C: a better marker for CVD risk assessment and
treatment. The National Cholesterol Education Program
Adult Treatment Panel III guidelines state that “In mostof LDL-C and non–HDL-C
expressed by different shades of color, which represent increasing densities of
Figure 2
Treatment Category Reclassiﬁcation Using Guideline-Based Non–HDL-C Cutpoints Versus Percentile-Based Cutpoints
for the Total Population
Four triglyceride categories were analyzed and each assigned a color as depicted. N ¼ 1,310,440.
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1963persons with triglycerides <200 mg/dl, adding VLDL-C to
LDL-C would be expected to provide little additional power
to predict CVD” (3); this is a disputable statement given the
increasing prevalence of obesity, diabetes mellitus, and
metabolic syndrome. Non–HDL-C represents the aggre-
gate cholesterol content of apolipoprotein B–containing
atherogenic lipoproteins, including LDL, VLDL,
intermediate-density lipoprotein, remnants, and lip-
oprotein(a); in principle, this is a broader, more inclusive
measure of atherogenic risk. Recent evidence suggests that
non–HDL-C is superior for risk prediction and might be
a more effective target for lipid-lowering therapy, particu-
larly in high-risk patients (12–15). A meta-analysis of
233,455 patients showed that non–HDL-C is a more potent
marker of CVD risk than LDL-C (16). Calculating the
number of clinical events prevented by a high-risk treatment
regimen in those in the >70th percentile of the U.S. adult
population, Sniderman et al. (16) suggested that a non–
HDL-C based strategy may prevent 300,000 more events
than an LDL-C strategy over a 10-year period.
In addition, measurement of the non–HDL-C level has
no additional cost or inconvenience because it is easily
calculated from the standard lipid proﬁle without the needfor prior fasting. Moreover, the adoption of non–HDL-C
across all levels of triglycerides would substantially simplify
implementation of clinical guidelines.
Potential implications for guideline development.
Guideline-based non–HDL-C cutpoints are based on the
assumption that a normal VLDL cholesterol level exists
when triglyceride levels are <150 mg/dl, which is <30 mg/dl
as estimated by the Friedewald formula (3). More recent
evidence suggests that a biologically optimal fasting triglyc-
eride level is <100 mg/dl (17); thus, a normal VLDL
cholesterol level is likely closer to 20 mg/dl, also suggesting
that non–HDL-C cutpoints should be 20 mg/dl higher than
LDL-C cutpoints.
Studying patients with acute coronary syndromes,
Ballantyne et al. suggested that the current non–HDL-C
goal should be lowered by 8 to 10 mg/dl to match LDL-
C and apolipoprotein B treatment goals in the very-high-
risk category (18). Other reports have recommended
lowering non–HDL-C cutpoints to match percentiles of
LDL-C cutpoints (6,7). In our study, the non–HDL-C
values with percentile equivalence to LDL-C cutpoints
of 100 and 70 mg/dl were 125 and 93 mg/dl, respec-
tively. Therefore, non–HDL-C cutpoints may need to
Figure 3
Treatment Category Reclassiﬁcation Using Guideline-Based Non–HDL-C Cutpoints Versus Percentile-Based Cutpoints at
Secondary Prevention LDL-C Range
LDL-C levels: (A) <70 mg/dl and (B) 70 to 99 mg/dl.
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1964be lowered by 5 mg/dl and 7 mg/dl for the high-risk and
very-high-risk categories, respectively. This leads to
substantial upward reclassiﬁcation of patients, particularly
at concurrent high triglyceride levels. For example, of
patients with LDL-C levels <70 mg/dl and concurrent
triglyceride levels of 150 to 199 mg/dl, more than twice
as many patients were reclassiﬁed upward when the non–
HDL-C cutpoint was lowered from 100 to 93 mg/dl
(Fig. 3A).
Our study also showed that the triglyceride thres-
hold in the current guidelines of 200 mg/dl for using
non–HDL-C as a secondary treatment target may need tobe lowered given that considerable upward reclassiﬁcation
occurs also at triglyceride levels of 150 to 199 mg/dl (Fig. 2).
Study limitations. We have limited clinical and demo-
graphic data regarding the full risk factor proﬁle of our
population. Therefore, reclassiﬁcation analyses are inferred
on the basis of the lipid proﬁle only and we cannot deter-
mine its impact on clinical outcomes.
The nearly superimposable age, sex, and lipid distribu-
tions between the samples from the VLDL study and the
National Health and Nutrition Examination Survey suggest
that our study comprises a reasonable population of patients
engaged in prevention and treatment of atherosclerosis, not
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1965a special population that underwent VAP testing. We do not
know the percentage of patients who were taking a statin.
Some samples in our study may have been acquired in
a nonfasting state, but this is not uncommon in routine
practice.
Despite focusing on upward reclassiﬁcation in accor-
dance with current guidelines, there was considerable
downward reclassiﬁcation in patients with triglyceride
levels <150 mg/dl (Fig. 2). The signiﬁcance of downward
reclassiﬁcation remains unclear in the literature and
current guidelines, and whether these patients should be
treated to LDL-C versus non–HDL-C goal needs further
scrutiny.
Conclusions
Our study of 1.3 million patients builds on prior evidence
that there is signiﬁcant patient-level discordance between
percentiles of LDL-C and non–HDL-C, particularly
when accuracy is most crucial, at lower LDL-C and
higher triglyceride levels. Therefore, lowering conventional
non–HDL-C cutpoints for high-risk patients to match
percentiles of LDL-C cutpoints as well as wider adoption of
non–HDL-C in clinical practice may potentially improve
secondary prevention outcomes and residual risk assessment
and treatment.
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